Withanolides: Promising candidates for cancer therapy

Qiang Zhang,YongKang Yuan,Shijie Cao,Ning Kang,Feng Qiu

DOI: https://doi.org/10.1002/ptr.8090

IF: 6.388

2024-01-05

Phytotherapy Research

Abstract:An overview of the representative compounds of withanolides as well as their anticancer mechanisms, regulated signaling pathways, and their potential for clinical translation. Natural products have played a significant role throughout history in the prevention and treatment of numerous diseases, particularly cancers. As a natural product primarily derived from various medicinal plants in the Withania genus, withanolides have been shown in several studies to exhibit potential activities in cancer treatment. Consequently, understanding the molecular mechanism of withanolides could herald the discovery of new anticancer agents. Withanolides have been studied widely, especially in the last 20 years, and attracted the attention of numerous researchers. Currently, over 1200 withanolides have been classified, with approximately a quarter of them having been reported in the literature to be able to modulate the survival and death of cancer cells through multiple avenues. To what extent, though, has the anticancer effects of these compounds been studied? How far are they from being developed into clinical drugs? What are their potential, characteristic features, and challenges? In this review, we elaborate on the current knowledge of natural compounds belonging to this class and provide an overview of their natural sources, anticancer activity, mechanism of action, molecular targets, and implications for anticancer drug research. In addition, direct targets and clinical research to guide the design and implementation of future preclinical and clinical studies to accelerate the application of withanolides have been highlighted.

pharmacology & pharmacy,chemistry, medicinal